Latest & greatest articles for pneumonia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pneumonia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pneumonia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pneumonia

561. NOW(R) S. pneumoniae test

NOW(R) S. pneumoniae test NOW(R) S. pneumoniae test NOW(R) S. pneumoniae test Alberta Heritage Foundation for Medical Research Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Alberta Heritage Foundation for Medical Research. NOW(R) S. pneumoniae test. Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR). Emerging Technology (...) Report. 2000 Authors' objectives This report aims to summarise the available evidence on the NOW(R) S. pneumoniae test. Authors' conclusions Streptococcus pneumoniae is a leading cause of bacterial pneumonia; however it is not the only cause. Determination of the pathogen responsible for pneumonia allows for the correct choice of treatment. This is particularly important with the rising incidence of antibiotic resistance. The NOW(R) test allows accurate diagnosis from a urine sample in approximately

2000 Health Technology Assessment (HTA) Database.

562. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. (Abstract)

A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. Large variations exist among hospitals in the use of treatment resources for community-acquired pneumonia (CAP). Lack of a common approach to the diagnosis and treatment of CAP has been cited as an explanation for these variations.To determine if use of a critical pathway improves the efficiency of treatment

2000 JAMA Controlled trial quality: predicted high

563. Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs

Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs Weycker D, Richardson E, Oster G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of a heptavalent pneumococcal conjugate vaccine (PNCRM7) in children aged younger than 5 years, for the prevention of acute otitis media (AOM), community-acquired pneumonia (CAP), and tympanostomy and related procedures (TRP). Type of intervention Primary prevention (paediatric vaccination). Economic study type Cost

2000 NHS Economic Evaluation Database.

564. Heat-and-moisture exchangers used with biweekly circuit tubing changes: effect on costs and pneumonia rates Full Text available with Trip Pro

Heat-and-moisture exchangers used with biweekly circuit tubing changes: effect on costs and pneumonia rates Heat-and-moisture exchangers used with biweekly circuit tubing changes: effect on costs and pneumonia rates Heat-and-moisture exchangers used with biweekly circuit tubing changes: effect on costs and pneumonia rates Salemi C, Padilla S, Canola T, Reynolds D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) not reported. Analysis of effectiveness The basis of the analysis of the clinical study was not reported. The outcome measure used in the analysis was the rate of VAP. This was estimated from 1989 to 1999. The HME was introduced in 1991. The criteria for determining the presence of pneumonia were based on guidelines of the Centers for Disease Control and Prevention. The baseline comparability of the groups of patients was not discussed. Effectiveness results The rate of VAP was 8% in 1991

2000 NHS Economic Evaluation Database.

565. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials

Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials Messori A, Trippoli (...) S, Vaiani M, Gorini M, Corrado A Authors' objectives To determine the effectiveness of ranitidine and sucralfate in the prevention of stress ulcer in critical patients, and to assess if these treatments affect the risk of nosocomial pneumonia. Searching The authors searched MEDLINE from 1966 to June 2000 using the keywords 'stress', 'pneumonia', 'ranitidine' and 'sucralfate'. Randomised studies were identified using the keywords 'randomized controlled trial' or 'random'. The search

2000 DARE.

566. Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome

Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute (...) of mechanical ventilation and intensive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome (ARDS). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with acute respiratory failure severe enough to require ventilator support. The study sample comprised patients with acute respiratory failure enrolled in the Study to Understand Prognoses and Preferences for Outcomes

2000 NHS Economic Evaluation Database.

567. [Cost-effectiveness study of ceftriaxone and cefotaxime for the treatment of community acquired pneumonia]

[Cost-effectiveness study of ceftriaxone and cefotaxime for the treatment of community acquired pneumonia] Estudio de costo-efectividad de ceftriaxona y cefotaxima en el tratamiento de neumonia adquirida en la comunidad [Cost-effectiveness study of ceftriaxone and cefotaxime for the treatment of community acquired pneumonia] Estudio de costo-efectividad de ceftriaxona y cefotaxima en el tratamiento de neumonia adquirida en la comunidad [Cost-effectiveness study of ceftriaxone and cefotaxime (...) health system. Source of funding None given. Bibliographic details Garcia-Contreras F, Del-Angel-Garcia G, Cuenca A R, Malvaez-Valdes M, Yanez A V, Amato D. Estudio de costo-efectividad de ceftriaxona y cefotaxima en el tratamiento de neumonia adquirida en la comunidad. [Cost-effectiveness study of ceftriaxone and cefotaxime for the treatment of community acquired pneumonia] Revista de Investigacion Clinica 2000; 52(4): 418-426 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Cefotaxime

2000 NHS Economic Evaluation Database.

568. Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia

Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia Najib M M, Stein G E, Goss T F Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology in the study was sparfloxacin, a new fluoroquinolone used as an oral antimicrobial treatment for community-acquired pneumonia (CAP). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population

2000 NHS Economic Evaluation Database.

569. Prolonged use of heat and moisture exchangers does not affect device efficiency or frequency rate of nosocomial pneumonia

Prolonged use of heat and moisture exchangers does not affect device efficiency or frequency rate of nosocomial pneumonia Prolonged use of heat and moisture exchangers does not affect device efficiency or frequency rate of nosocomial pneumonia Prolonged use of heat and moisture exchangers does not affect device efficiency or frequency rate of nosocomial pneumonia Davis K, Evans S L, Campbell R S, Johannigman J A, Luchette F A, Porembka D T, Branson R D Record Status This is a critical abstract (...) in the analysis of effectiveness was not explicitly reported. The health outcome measures were the frequency rate of nosocomial pneumonia and bacterial colonisation, resistance, humidity, duration of use, and clinical evidence of device efficacy (number of suctionings per day, daily volume of saline instilled, and daily volume of secretions suctioned; the number of patients with thin, moderate, and thick secretions; and tracheal tube occlusions). The three study groups were comparable in terms of demographic

2000 NHS Economic Evaluation Database.

570. Pharmaceutical economics & health policy: economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin

Pharmaceutical economics & health policy: economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin Pharmaceutical economics & health policy: economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin Pharmaceutical economics & health policy: economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin Palmer C S, Zhan C, Elixhauser A, Halpern M T, Rance L, Feagan B G, Marrie T J (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A critical pathway (CP) designed to manage community-acquired pneumonia (CAP) more efficiently than conventional care was examined. The CP included three elements: the use

2000 NHS Economic Evaluation Database.

571. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis undergoing immunosuppressive therapy

Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis undergoing immunosuppressive therapy Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis undergoing immunosuppressive therapy Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis undergoing immunosuppressive therapy Chung J B, Armstrong K, Schwartz J S (...) carinii pneumonia (PCP). No prophylaxis was compared with combined trimethoprim (160 mg) and sulfamethoxazole (800 mg) (TMP/SMX), taken 3 times a week. No prophylaxis was also compared with a regime in which TMP/SMX was taken but, when an adverse drug reaction (ADR) occurred, the combination was replaced with aerosolised pentamidine (300 mg monthly). Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population A hypothetical cohort of patients with WG aged 35

2000 NHS Economic Evaluation Database.

572. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. (Abstract)

Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. Risk factors for nosocomial pneumonia, such as gastro-oesophageal reflux and subsequent aspiration, can be reduced by semirecumbent body position in intensive-care patients. The objective of this study was to assess whether the incidence of nosocomial pneumonia can also be reduced by this measure.This trial was stopped after the planned interim analysis. 86 intubated (...) and mechanically ventilated patients of one medical and one respiratory intensive-care unit at a tertiary-care university hospital were randomly assigned to semirecumbent (n=39) or supine (n=47) body position. The frequency of clinically suspected and microbiologically confirmed nosocomial pneumonia (clinical plus quantitative bacteriological criteria) was assessed in both groups. Body position was analysed together with known risk factors for nosocomial pneumonia.The frequency of clinically suspected

1999 Lancet Controlled trial quality: predicted high

573. Cost-effectiveness analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumonia

Cost-effectiveness analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumonia Cost-effectiveness analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumonia Cost-effectiveness analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumonia Ambrose P G, Richerson M A, Stanton M, Bui K, Nicolau D P, Nightingale C H, Quintiliani R Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of third and fourth generation cephalosporins in the treatment of hospital acquired pneumonia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients

1999 NHS Economic Evaluation Database.

574. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia

Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia Ailani R K, Agastya G, Ailani R K, Mukunda B N, Shekar R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Doxycycline for hospitalised patients with community-acquired pneumonia. The dosage was 100mg given intravenously every 12 hours. This was switched to 100mg orally every 12 hours for patients in the intervention group who improved. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study

1999 NHS Economic Evaluation Database.

575. Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group. (Abstract)

Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group. Azithromycin in combination with sulphonamides is active against Pneumocystis carinii pneumonia (PCP) in animals. We assessed the clinical efficacy of azithromycin for PCP prophylaxis in human beings.We identified HIV-1-infected patients with PCP during a prospective randomised trial comparing azithromycin, rifabutin, and the two drugs in combination

1999 Lancet Controlled trial quality: uncertain

576. Protected specimen brush or bronchoalveolar lavage to diagnose bacterial nosocomial pneumonia in ventilated adults: a meta-analysis

Protected specimen brush or bronchoalveolar lavage to diagnose bacterial nosocomial pneumonia in ventilated adults: a meta-analysis Protected specimen brush or bronchoalveolar lavage to diagnose bacterial nosocomial pneumonia in ventilated adults: a meta-analysis Protected specimen brush or bronchoalveolar lavage to diagnose bacterial nosocomial pneumonia in ventilated adults: a meta-analysis de Jaeger A, Litalien C, Lacroix J, Guertin M C, Infante-Rivard C Authors' objectives To compare (...) the diagnostic value for bacterial nosocomial pneumonia (BNP) of: quantitative culture (colony-forming units per millilitre, CFU/mL) of respiratory secretions collected with a bronchoscopic protected specimen brush (PSB); quantitative culture (CFU/mL) of a bronchoscopic bronchoalveolar lavage (BAL); and the percentage of infected cells (IC) in BAL. Searching MEDLINE was searched for English and French literature, using the terms: 'bronchoalveolar lavage', 'critical care', 'cross-infection', 'diagnosis

1999 DARE.

577. Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials

Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials Bhutta Z A, Black R E, Brown K H, Gardner J M, Gore S (...) , Hidayat A, Khatun F, Martorell R, Ninh N X, Penny M E, Rosado J L, Roy S K, Ruel M, Sazawal S, Shankar A Authors' objectives To assess the effects of zinc supplementation in the prevention of diarrhea and pneumonia in children in developing countries. Searching MEDLINE, SCI-SCIMATE and Current Contents were searched. References from papers were screened. Contact was made with possible funding agencies and with investigators in micronutrition. Study selection Study designs of evaluations included

1999 DARE.

578. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study

Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective (...) patients with uncomplicated community-acquired pneumonia (CAP): A 10-day treatment course comprising intravenous (IV) administration of cefuroxime (Zinacef; Glaxo Wellcome Inc, Research Triangle Park, NC; 750mg every 8 hours) during the two first days, and followed by 8 days of oral cefuroxime axetil (Ceftin; Glaxo Wellcome Inc; 500 mg every 12 hours). A 7-day treatment, comprising two days of IV cefuroxime, followed by 5 days of cefuroxime axetil (using the same doses as for the 10 day treatment

1999 NHS Economic Evaluation Database.

579. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalised patients with severe pneumonia

Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalised patients with severe pneumonia Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalised patients with severe pneumonia Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalised patients with severe pneumonia Caldwell J W, Singh (...) S, Johnson R H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Use of intravenous ciprofloxacin or imipenem therapy in the treatment of hospitalised patients with severe pneumonia. Type of intervention Treatment. Economic study

1999 NHS Economic Evaluation Database.

580. Utility of blood cultures in community-acquired pneumonia requiring hospitalization: influence of antibiotic treatment before admission

Utility of blood cultures in community-acquired pneumonia requiring hospitalization: influence of antibiotic treatment before admission Utility of blood cultures in community-acquired pneumonia requiring hospitalization: influence of antibiotic treatment before admission Utility of blood cultures in community-acquired pneumonia requiring hospitalization: influence of antibiotic treatment before admission Glerant J C, Hellmuth D, Schmit J L, Ducroix J P, Jounieaux V Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated the use of microbiological blood cultures for the diagnosis of patients hospitalised for moderate community-acquired pneumonia (CAP). The comparator was no microbiological blood cultures

1999 NHS Economic Evaluation Database.